Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05277402 | ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors | PHASE1 | COMPLETED | 6 | — | — | Feb 9, 2022 | Dec 1, 2022 | Feb 26, 2024 | 2 | United States |
| NCT04501276 | A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients | PHASE1 | COMPLETED | 72 | — | — | Sep 23, 2020 | Nov 30, 2025 | Jan 8, 2026 | 4 | United States, Australia |
Number of participants experiencing dose-limiting toxicities escalating dose levels in adults with advanced / metastatic solid tumor
Number of participants with adverse events as assessed by CTCAE v5.0
| Arm | Type | Description |
|---|---|---|
| Dose escalation | EXPERIMENTAL | ADG116 combination treatment with pembrolizumab (KEYTRUDA®), both drugs will be administered in each cohort. |
| Part A : Dose escalation of ADG116 monotherapy | EXPERIMENTAL | - |
| Part B : Dose escalation of ADG116 combined with anti PD1 drug | EXPERIMENTAL | - |
| Part C : Dose escalation of ADG116 combined with ADG106 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ADG116 | DRUG | IV infusion |
| ADG106 | DRUG | For the ADG116-ADG106 combination regimen, ADG116 and ADG106 will be administered until disease progression, intolerable toxicities, or withdrawal of consent, or up to 2 years. |
| anti PD1 drug | DRUG | For the ADG116-anti PD1 combination regimen, ADG116 and anti PD1 will be administered until disease progression, intolerable toxicities, or withdrawal of consent, or up to 2 years. |
Inclusion Criteria: * Patients must meet all of the following inclusion criteria to be eligible for participation in this study: 1. ≥ 18 years of age at the time of informed consent. 2. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 with no deterioration over the previous ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |